Compare EPAC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPAC | NUVB |
|---|---|---|
| Founded | 1910 | 2018 |
| Country | United States | United States |
| Employees | N/A | 298 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1994 | N/A |
| Metric | EPAC | NUVB |
|---|---|---|
| Price | $33.46 | $4.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $48.00 | $11.38 |
| AVG Volume (30 Days) | 345.8K | ★ 3.8M |
| Earning Date | 03-25-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.12% | N/A |
| EPS Growth | ★ 8.97 | N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $616,899,000.00 | N/A |
| Revenue This Year | $5.60 | $203.82 |
| Revenue Next Year | $5.56 | $58.18 |
| P/E Ratio | $49.54 | ★ N/A |
| Revenue Growth | ★ 4.65 | N/A |
| 52 Week Low | $32.35 | $1.57 |
| 52 Week High | $45.00 | $9.75 |
| Indicator | EPAC | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 50.35 |
| Support Level | $32.71 | $4.07 |
| Resistance Level | $36.56 | $5.16 |
| Average True Range (ATR) | 0.73 | 0.31 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 41.13 | 51.30 |
Enerpac Tool Group Corp provides high-precision hydraulic and mechanical tools, controlled-force products, and heavy lifting solutions. Operating mainly through its Industrial Tools & Services (IT&S) segment, the company designs, manufactures, and distributes branded tools, and offers maintenance, bolting, machining, joint integrity, and equipment rental services across industries such as oil & gas, manufacturing, power generation, and infrastructure. Its key products include hydraulic cylinders, pumps, torque wrenches, and bolt tensioners under the brands ENERPAC and HYDRATIGHT. The company serves customers internationally, with operations in the USA, Australia, Brazil, Germany, Saudi Arabia, the United Kingdom, and other countries, deriving the majority of its revenue from the USA.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.